Health Canada

Health Canada

October 13, 2010 13:28 ET

Update: All Marketed Sibutramine Drugs Voluntarily Withdrawn in Canada

OTTAWA, ONTARIO--(Marketwire - Oct. 13, 2010) - Further to Health Canada's October 8, 2010, communication ( http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2010/2010_169-eng.php ) on the voluntary recall by Abbott Laboratories of Meridia(R) (the brand name for the weight-loss drug sibutramine), Health Canada is updating healthcare practitioners and Canadians with respect to the two generic forms of sibutramine drugs authorized in Canada: Apo-sibutramine and Novo-sibutramine.

Apotex Inc., the manufacturer of Apo-sibutramine, has agreed to voluntarily withdraw this drug from the Canadian market. Teva Canada Ltd., the manufacturer of Novo-sibutramine, has confirmed to Health Canada that it has not marketed this drug in Canada, i.e., Novo-sibutramine is not available for sale on the Canadian market.

As with Meridia(R), patients currently taking Apo-sibutramine should contact their healthcare practitioner at their earliest convenience regarding potential alternatives. Pharmacists with questions regarding their current supply of Apo-sibutramine should contact Apotex Inc. directly at 1-877-427-6839 (1-877-4-APOTEX), extension 1601. Patients with questions regarding their current supply should contact their pharmacist.

Aussi disponible en français

Contact Information

  • Media Inquiries:
    Health Canada
    613-957-2983
    or
    Public Inquiries:
    613-957-2991
    1-866 225-0709